Last reviewed · How we verify
NCT03152448: P-PROVE
Prospective Prolaris Value and Efficacy
trial testing Prolaris in Prostate Cancer in 1,511 participants. Terminated before completion.
21 March 2022
Quick facts
| Lead sponsor | Myriad Genetic Laboratories, Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 1,511 |
| Start date | 1 September 2015 |
| Primary completion | 21 March 2022 |
| Estimated completion | 21 March 2022 |
| Sites | 12 locations across United States |
Drugs / interventions tested
- Prolaris
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Myriad Genetic Laboratories, Inc.
Who can join
18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03152448
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Myriad Genetic Laboratories, Inc. trials
Trials by the same sponsor.
- NCT04016935 — EndoPredict® Extended Endocrine Trial (EXET) · terminated
- NCT04015102 — A Registry for Hereditary Cancer Risk Assessment and Genetic Testing · completed
- NCT03511235 — Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing · completed
- NCT03290508 — Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer · terminated
- NCT03081455 — Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03152448 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Myriad Genetic Laboratories, Inc.
- Last refreshed: 13 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03152448.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing